We demonstrated that the TG/HDL ratio, IL-2, IL-6, IL-17A, and INF-γ were significantly greater in subjects with MetS than in those without MetS, and may therefore be used as biomarkers to predict future cardiovascular disease. The gene discussed is IL17A; the disease is metabolic syndrome.